Stoke Therapeutics, Inc. Shareholders' Equity
Stoke Therapeutics, Inc. (STOK) had Shareholders' Equity of $345.55 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-03
- 2026-06-30: Stockholders' Equity Attributable to Parent $345.55M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $394.88M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $352.46M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $308.11M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $345.55M 10-Q · filed 2026-08-03 |
| 2026-03-31 | $394.88M 10-Q · filed 2026-08-03 |
| 2025-12-31 | $352.46M 10-Q · filed 2026-08-03 |
| 2025-09-30 | $308.11M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $334.94M 10-Q · filed 2026-08-03 |
| 2025-03-31 | $350.07M 10-Q · filed 2026-08-03 |
| 2024-12-31 | $229.02M 10-Q · filed 2026-08-03 |
| 2024-09-30 | $232.11M 10-Q · filed 2025-11-04 |
| 2024-06-30 | $242.71M 10-Q · filed 2025-11-04 |
| 2024-03-31 | $140.34M 10-Q · filed 2025-11-04 |
| 2023-12-31 | $159.56M 10-K · filed 2026-03-16 |
| 2023-09-30 | $173.00M 10-Q · filed 2024-11-05 |
| 2023-06-30 | $190.19M 10-Q · filed 2024-11-05 |
| 2023-03-31 | $213.82M 10-Q · filed 2024-11-05 |
| 2022-12-31 | $184.85M 10-K · filed 2025-03-18 |
| 2022-09-30 | $204.14M 10-Q · filed 2023-11-07 |
| 2022-06-30 | $224.32M 10-Q · filed 2023-11-07 |
| 2022-03-31 | $239.98M 10-Q · filed 2023-11-07 |
| 2021-12-31 | $217.78M 10-K · filed 2024-03-25 |
| 2021-09-30 | $237.51M 10-Q · filed 2022-11-14 |
| 2021-06-30 | $255.07M 10-Q · filed 2022-11-14 |
| 2021-03-31 | $272.46M 10-Q · filed 2022-11-14 |
| 2020-12-31 | $286.08M 10-K · filed 2023-03-06 |
| 2020-09-30 | $192.53M 10-Q · filed 2021-11-08 |
| 2020-06-30 | $203.40M 10-Q · filed 2021-11-08 |
| 2020-03-31 | $214.34M 10-Q · filed 2021-11-08 |
| 2019-12-31 | $224.43M 10-K · filed 2022-03-10 |
| 2019-09-30 | $233.68M 10-Q · filed 2020-11-12 |
| 2019-06-30 | $241.54M 10-Q · filed 2020-11-12 |
| 2019-03-31 | $99.58M 10-Q · filed 2020-11-12 |
| 2018-12-31 | $105.07M 10-K · filed 2021-03-09 |
| 2018-09-30 | $19.39M 10-Q · filed 2019-11-12 |
| 2018-06-30 | $9.29M 10-Q · filed 2019-11-12 |
| 2018-03-31 | $12.22M 10-Q · filed 2019-11-12 |
| 2017-12-31 | -$1.29M 10-K · filed 2020-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |